Overall survival benefit of abiraterone in mHSPC is maintained for 7 years Presented ByProf. Gerhardt Attard, UCL Cancer Institute London, UK TrialPhase 3, STAMPEDE ConferenceESMO 2022 17 November, 2022 00:23